Key facts
- Beijietai’s last known valuation is $328.4M (Mar 2025).
- It has raised $18.4M; the latest was Early Stage VC ($18.4M) in Mar 2025.
- Notable investors include Guolian Investment, Staidson (Beijing) Biopharmaceuticals Company.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Beijietai
- ·The full record, as it builds
Funding rounds
No funding rounds for Beijietai are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Beijietai
Developer of pharmaceutical treatments designed to target diseases such as hemophilia and other immune-mediated bleeding disorders. The company's therapeutics treat internal bleeding from hemophilia, enabling healthcare providers to improve patient outcomes.
- Sector
- Healthcare
- HQ
- Wuxi, China
- Founded
- 2024
- Ownership
- Privately Held (backing)
Beijietai doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Beijietai shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Beijietai in its N-PORT filings yet. We sweep new filings monthly.